Accordingly, several monoclonal antibodies (mAbs) targeting PD-1 (pembrolizumab and nivolumab) and PD-L1 (atezolimumab) interaction have received FDA approval for the treatment of various lethal cancers including metastatic melanoma, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, and breast cancer, among others (218). The gene discussed is CD274; the disease is cancer.